Regeneron Pharmaceuticals, Inc. $REGN Shares Sold by Capital Group Private Client Services Inc.

Key Points

• Capital Group Private Client Services cut its position in Regeneron by 87.3% in Q3, selling 19,965 shares and leaving it with 2,907 shares valued at $1.635 million.
• Company insiders sold 5,274 shares totaling $4.14 million over the last 90 days — notably SVP Jason Pitofsky (2,036 shares at $778.52) and Director Huda Y. Zoghbi (1,638 shares at $781.33) — and insiders now own 7.02% of REGN.
• Analysts are broadly positive with a consensus Moderate Buy and average price target of $802.27, after Regeneron reported an earnings beat and the company raised its quarterly dividend to $0.94.

Capital Group Private Client Services Inc. cut its position in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN - Free Report) by 87.3% during the third quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The fund owned 2,907 shares of the biopharmaceutical company's stock after selling 19,965 shares during the period. Capital Group Private Client Services Inc.'s holdings in Regeneron Pharmaceuticals were worth $1,635,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other hedge funds and other institutional investors have also modified their holdings of REGN. Salomon & Ludwin LLC acquired a new stake in Regeneron Pharmaceuticals in the third quarter valued at $27,000. Migdal Insurance & Financial Holdings Ltd. purchased a new stake in Regeneron Pharmaceuticals during the 2nd quarter worth about $31,000. Caitlin John LLC acquired a new position in shares of Regeneron Pharmaceuticals during the 3rd quarter worth about $34,000. Traub Capital Management LLC purchased a new position in shares of Regeneron Pharmaceuticals in the 2nd quarter valued at about $38,000. Finally, E Fund Management Hong Kong Co. Ltd. increased its holdings in shares of Regeneron Pharmaceuticals by 87.5% in the 3rd quarter. E Fund Management Hong Kong Co. Ltd. now owns 75 shares of the biopharmaceutical company's stock valued at $42,000 after acquiring an additional 35 shares during the last quarter. 83.31% of the stock is currently owned by institutional investors and hedge funds.

Insider Buying and Selling

In other news, SVP Jason Pitofsky sold 2,036 shares of the company's stock in a transaction that occurred on Monday, February 9th. The stock was sold at an average price of $778.52, for a total transaction of $1,585,066.72. Following the completion of the sale, the senior vice president owned 4,272 shares in the company, valued at $3,325,837.44. This represents a 32.28% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Also, Director Huda Y. Zoghbi sold 1,638 shares of the stock in a transaction on Thursday, February 19th. The stock was sold at an average price of $781.33, for a total value of $1,279,818.54. Following the sale, the director directly owned 1,703 shares of the company's stock, valued at approximately $1,330,604.99. This represents a 49.03% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Insiders sold a total of 5,274 shares of company stock valued at $4,142,738 over the last 90 days. Insiders own 7.02% of the company's stock.

Wall Street Analyst Weigh In

Several equities research analysts recently weighed in on the company. Scotiabank boosted their target price on Regeneron Pharmaceuticals from $650.00 to $770.00 and gave the stock a "sector perform" rating in a research note on Monday, November 24th. Truist Financial dropped their price target on shares of Regeneron Pharmaceuticals from $820.00 to $818.00 and set a "buy" rating on the stock in a research note on Monday, February 2nd. Royal Bank Of Canada raised their price objective on shares of Regeneron Pharmaceuticals from $745.00 to $765.00 and gave the stock a "sector perform" rating in a report on Monday, March 2nd. JPMorgan Chase & Co. boosted their price objective on shares of Regeneron Pharmaceuticals from $850.00 to $950.00 and gave the stock an "overweight" rating in a research report on Monday, February 2nd. Finally, Bank of America raised shares of Regeneron Pharmaceuticals from an "underperform" rating to a "buy" rating and increased their target price for the company from $627.00 to $860.00 in a research report on Wednesday, January 7th. Two equities research analysts have rated the stock with a Strong Buy rating, fifteen have issued a Buy rating and nine have assigned a Hold rating to the company. Based on data from MarketBeat, the company has a consensus rating of "Moderate Buy" and an average price target of $802.27.

Regeneron Pharmaceuticals Trading Down 1.2%

NASDAQ REGN opened at $772.03 on Wednesday. The company has a debt-to-equity ratio of 0.09, a quick ratio of 3.39 and a current ratio of 4.13. The firm has a market cap of $81.62 billion, a PE ratio of 18.58, a P/E/G ratio of 2.10 and a beta of 0.41. Regeneron Pharmaceuticals, Inc. has a one year low of $476.49 and a one year high of $821.11. The firm's fifty day moving average is $770.79 and its two-hundred day moving average is $692.02.

Regeneron Pharmaceuticals (NASDAQ:REGN - Get Free Report) last announced its earnings results on Friday, January 30th. The biopharmaceutical company reported $11.44 earnings per share for the quarter, topping the consensus estimate of $10.74 by $0.70. Regeneron Pharmaceuticals had a net margin of 31.41% and a return on equity of 13.04%. The business had revenue of $3.88 billion during the quarter, compared to the consensus estimate of $3.76 billion. During the same quarter in the prior year, the firm earned $12.07 earnings per share. The business's quarterly revenue was up 2.5% compared to the same quarter last year. Analysts expect that Regeneron Pharmaceuticals, Inc. will post 35.92 earnings per share for the current year.

Regeneron Pharmaceuticals Increases Dividend

The business also recently disclosed a quarterly dividend, which was paid on Thursday, March 5th. Shareholders of record on Friday, February 20th were given a dividend of $0.94 per share. This represents a $3.76 dividend on an annualized basis and a yield of 0.5%. The ex-dividend date of this dividend was Friday, February 20th. This is a positive change from Regeneron Pharmaceuticals's previous quarterly dividend of $0.88. Regeneron Pharmaceuticals's payout ratio is 9.05%.

About Regeneron Pharmaceuticals

Regeneron Pharmaceuticals, Inc NASDAQ: REGN is a U.S.-based biotechnology company founded in 1988 and headquartered in Tarrytown, New York. It focuses on discovering, developing, manufacturing and commercializing medicines for serious medical conditions. The company combines laboratory research, clinical development and in-house manufacturing to advance a pipeline of biologic therapies across multiple therapeutic areas.

Regeneron is known for its proprietary drug discovery technologies, including its VelocImmune platform, which is used to generate fully human monoclonal antibodies.

Want to see what other hedge funds are holding REGN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.